NEW YORK, June 19, 2024 /PRNewswire/ — SMITM CAPITAL MARKETS LTD, has announced a significant agreement with Mid-Atlantic BioTherapeutics, Inc. (MABT), a clinical-stage ready US biopharmaceutical company. This agreement entails a capital commitment of USD 5 million, fueling MABT’s…